REGN24493 / Regeneron - LARVOL DELTA

In-Vitro Properties of REGN24493, a Novel TSHR-Blocking Monoclonal Antibody for the Treatment of Graves’ Disease and Thyroid Eye Disease (ETA 2026) - "In summary, REGN24493 demonstrated specific binding to cell-surface TSHR from human and tested non-human species. REGN24493 was able to block TSHR activation by its canonical ligand and TSAbs, a diagnostic hallmark and key drivers of GD and TED."

Preclinical • Endocrine Disorders • Grave’s Disease • Immunology • Ophthalmology • Thyroid Eye Disease • TSHR

A Novel TSHR-Blocking Antibody Which Effectively Reduces Hyperthyroidism and Proptosis in a Mouse Model of Graves’ and Thyroid Eye Disease (ETA 2026) - "These findings demonstrate that chronic M22 injections alone can induce both hyperthyroidism and proptosis in female mice. TSHR blockade effectively reduced hyperthyroidism and prevented TSAb-induced proptosis. These results suggest that REGN23415 and REGN24493 are potent TSHR blockers with therapeutic potential for GD and TED."

Preclinical • Endocrine Disorders • Grave’s Disease • Immunology • Ophthalmology • Thyroid Eye Disease • TSHR

REGN23415 and REGN24493: In-Vitro Properties of Two Novel TSHR-Blocking Monoclonal Antibodies for the Treatment of Graves' Disease and Thyroid Eye Disease (ATA 2026) - No abstract available

Preclinical • Endocrine Disorders • Grave’s Disease • Ophthalmology • Thyroid Eye Disease

In-Vitro Properties of REGN24493, A Novel TSHR Blocking Mab for the Treatment of Graves' Disease and Thyroid Eye Disease (ENDO 2026) - "In summary, REGN24493 demonstrated specific binding to cell surface TSHR from human and tested non-human species. REGN24493 was able to block TSHR activation by its canonical ligand and TSAbs, a diagnostic hallmark and key drivers of GD and TED."

Preclinical • Endocrine Disorders • Grave’s Disease • Ophthalmology • Thyroid Eye Disease • TSHR